Back to Search
Start Over
Amgen's GDNF misses in Phase II Parkinson's trial
- Source :
- BioWorld Week. July 5, 2004, Vol. 12 Issue 27, p2, 2 p.
- Publication Year :
- 2004
-
Abstract
- Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. The company's glial cell line-derived neurotrophic factor, also called CDNF, did not show [...]
Details
- Language :
- English
- ISSN :
- 19327765
- Volume :
- 12
- Issue :
- 27
- Database :
- Gale General OneFile
- Journal :
- BioWorld Week
- Publication Type :
- News
- Accession number :
- edsgcl.119115562